Akèy › Kansè nan tete › Michigan › Grand Rapids
Etid klinik pou Kansè nan tete nan Grand Rapids, MI
26 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote Grand Rapids (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- START - Midwest, Grand Rapids
A Study of PHST001 in Advanced Solid Tumors
Ap rekriteFaz 1
- START Center for Cancer Research - Midwest, Grand Rapids
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Ap rekrite
- Cancer & Hematology Centers, Grand Rapids
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Ap rekriteFaz 1
- BAMF Health Inc., Grand Rapids
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Ap rekriteFaz 1
- BAMF Health Inc., Grand Rapids
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Ap rekriteFaz 1/2
- START Midwest, LLC, Grand Rapids
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Ap rekriteFaz 3
- The Cancer & Hematology Centers, Grand Rapids
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Ap rekriteFaz 1
- START - Midwest Cancer Research Center, Grand Rapids
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Ap rekriteFaz 1
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Ap rekriteFaz 3
- Cancer & Hematology Centers of Western Michigan, Grand Rapids
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Ap rekriteFaz 3
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
A Study of MGC026 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- START Midwest, Grand Rapids
E-Mindfulness Approaches for Living After Breast Cancer
Ap rekriteFaz 3
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Ap rekriteFaz 1/2
- START Midwest, Grand Rapids
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Ap rekriteFaz 1
- BAMF Health, Grand Rapids
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- START Midwest, LLC, Grand Rapids
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- START Midwest, Grand Rapids
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
Ap rekriteFaz 2
- GSK Investigational Site, Grand Rapids
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Ap rekriteFaz 3
- Cancer and Hematology Centers of Western Michigan, Grand Rapids
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Ap rekriteFaz 3
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
- Trinity Health Grand Rapids Hospital, Grand Rapids
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids
- Trinity Health Grand Rapids Hospital, Grand Rapids
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Ap rekriteFaz 1/2
- START, Midwest, Grand Rapids
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Ap rekriteFaz 1/2
- START Midwest, Grand Rapids
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Ap rekriteFaz 3
- Spectrum Health at Butterworth Campus, Grand Rapids
Etid Kansè nan tete nan lòt vil
- New York City, NY136 etid
- Houston, TX126 etid
- Boston, MA112 etid
- Nashville, TN81 etid
- Los Angeles, CA73 etid
- Edison, NJ68 etid
- St. Louis, MO64 etid
- Queens, NY64 etid
- Durham, NC64 etid
- Chicago, IL59 etid
- Philadelphia, PA56 etid
- Dallas, TX55 etid
Lòt etid nan Grand Rapids
- Kansè Poumon ki pa ti selil44 etid
- Kansè kolorektal40 etid
- Kansè (tout kalite)28 etid
- Kansè ovè24 etid
- Kansè Metastatik22 etid
- Kansè pwostat19 etid
- Kansè Endomèt18 etid
- Kansè lestomak18 etid
- Kansè pankreyas18 etid
- Melanom17 etid
- Karsinòm selil skuamèz tèt ak kou15 etid
- Kansè tete negatif triple15 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.